The effective non-operative management of gall stones with bile acids was described in 1972. The predicted therapeutic revolution has not occurred, but the treatment has stimulated research into the clinical course and management of gall stone disease-with some unexpected results-and the latest findings were discussed at the eighth international bile acid meeting in Berne this summer.
Many ideas about the epidemiology of gall stones have had to be revised. For instance, two Italian studies of the prevalence of gall stones using ultrasound techniques have convincingly refuted the link said to exist with oral contraceptives. They confirmed earlier circumstantial evidence derived from the unaltered frequencies of gall stone disease in women of childbearing years in this century,2I and of cholecystectomy rates in women exposed to oral contraceptives,3 and from the lack of any association with treatment with oestrogens in men. 4 These new findings contradict earlier suggestive work based on less satisfactory epidemiological studies and on biliary lipid analysis. Clearly we should be slow to accept any statements about changes in gall stone disease. Nevertheless, one would have to be a calvinist not to welcome the news that a moderate intake of alcohol appears actually to protect against gall stones, as well as protecting against heart disease and prolonging life.5
The Italian ultrasound studies clearly incriminate obesity and higher parity in younger women as risk factors for gall stones. They also showed that only about one fifth of patients with gall stones have associated symptoms, which were more frequent in women with gall stones than in men. The Rome study also suggested that clofibrate does not cause gall stones and does protect men against heart disease-contrary to received wisdom.67
On the aetiology of gall stones attention has shifted from the important concepts of oversaturation of bile with cholesterol to what may be even more crucial-the nucleating factors which initiate the formation of gall stones. These are present in the gall bladder bile of patients with gall stones,9 but not in the gall bladder bile of obese patients without gall stones.'0 Another factor is the potential protective part played by antinucleating factors in bile, such as lipid vesicles and apolipoproteins I and II.
Ultrasound has now become the investigation of choice for gall bladder cholelithiasis-in hospitals where it is available. Though this technique may detect small calculi missed by oral cholecystography, the British Gallstone Study Group reported that the reverse is also true, so that both procedures may be needed before a patient can reasonably be dismissed as free of stones.' Population studies using ultrasound screens and follow up after oral cholecystography have shown that most gall stones are asymptomatic, so the clinician should be cautious in ordering investigations in patients with atypical symptoms.'2 Prophylactic cholecystectomy for silent gall stones may, indeed, decrease overall survival.'3 Perhaps even more disturbing is a prospective British survey which has shown that even where typical biliary pain was present before surgery, a year after cholecystectomy as many as 43% of patients rated their operation as less than completely successful. 14 The controversy whether cholecystectomy causes cancer of the colon remains unresolved. Quite possibly gall stone disease may be associated with various types of tumour of the intestines and the reproductive organs, but hospital necropsies also suggest spurious associations between diseases.'5 Cholecystectomy for gall stone disease is one of the most common abdominal operations in Western countries, and the rates show remarkable international and national variations. The overall need for gall bladder surgery is impossible to define on objective criteria, but we should probably welcome its recent decline in popularity in Britain after a long period of growth in frequency. ' Though some advances have been made in the medical treatment of stones in the common bile duct their poor prognosis (in contrast with the relatively benign outlook of gall bladder stones) means that they should be removed without delay. This usually will require endoscopic papillotomy, instrumentation of T tube tracts after cholecystectomy, or open choledochotomy. If an attempt is made to dissolve radiolucent stones by local infusion then monooctanoin is the treatment of choice and is very effective for stones of 7 mm or less in diameter.16 1 ' Other, more powerful solvents such as methyl-butyl-tertiary ether may be used in the future. In the few cases where oral treatment has to be chosen for stones in the common-duct ursodeoxycholic acid 750 mg daily for up to two years will dissolve stones in half the patients treated and also control symptoms effectively. '8 Adjuvant treatment with t4e terpene mixture Rowachol may possibly improve the success rate achieved with bile acid treatment alone. 19 For those patients selected for oral dissolution of stones in the gall bladder a dose of ursodeoxycholic acid of at least 500 mg daily is probably needed. Gall stone dissolution treatment is unreliable and often protracted, for continued treatment even after two years may eventually completely dissolve stones which had previously shown only a partial response.`9 Dietary treatment has been combined with chenodeoxycholic acid to speed up the dissolution rate,30 though the overall success rate was not improved and dietary treatment conferred no advantage when used with ursodeoxycholic acid.3' The rare condition cerebrotendinous xanthomatosis is an absolute indication for treatment with chenodeoxycholic acid, which not only corrects the abnormality of bile acid metabolism but also improves neurological performance.
Fourteen years on, therefore, we know that some gall stones can be dissolved but whether this is practical therapeutics is still under debate. The high rate of recurrence after treatment compromises the overall usefulness of the treatment, even though the recurrent stones are readily dissolved.32 The British Gallstone Study Group reported that dietary manipulation had not shown potential in preventing recurrence. Continued low dose chenodeoxycholic acid is ineffective.33 Continuation of alternate month full dose chenodeoxycholic acid treatment has shown promise in preventing recurrence,34 and the use of continuous low dose ursodeoxycholic acid is under investigation. At present the consensus seems to be that after confirmed complete dissolution of gall stones the clinician should await developments and then deal with recurrent symptoms as they arise. That advice may well have to be changed when the results of trials in progress are reported. 
